Wall Street Analysts See a 74.99% Upside in Rapport Therapeutics, Inc. (RAPP): Can the Stock Really Move This High? [Yahoo! Finance]
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
Rapport Therapeutics (NASDAQ:RAPP) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Rapport Therapeutics (NASDAQ:RAPP) is now covered by analysts at BTIG Research. They set a "buy" rating and a $47.00 price target on the stock.
Rapport Therapeutics (NASDAQ:RAPP) had its price target raised by analysts at Citizens Jmp from $77.00 to $80.00. They now have a "market outperform" rating on the stock.